Biomarin Pharmaceutical (FRA:BM8) Accounts Payable & Accrued Expense : €440 Mil (As of Mar. 2025)

View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Accounts Payable & Accrued Expense?

Biomarin Pharmaceutical's quarterly accounts payable & accrued expense declined from Sep. 2024 (€442 Mil) to Dec. 2024 (€365 Mil) but then increased from Dec. 2024 (€365 Mil) to Mar. 2025 (€440 Mil).

Biomarin Pharmaceutical's annual accounts payable & accrued expense increased from Dec. 2022 (€323 Mil) to Dec. 2023 (€399 Mil) but then declined from Dec. 2023 (€399 Mil) to Dec. 2024 (€365 Mil).

Biomarin Pharmaceutical Accounts Payable & Accrued Expense Historical Data

The historical data trend for Biomarin Pharmaceutical's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Accounts Payable & Accrued Expense Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

244.81

239.07

322.56

398.74

365.27

Biomarin Pharmaceutical Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															384.25	375.76	442.21	365.27	440.45

Biomarin Pharmaceutical Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Biomarin Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy 0HNC:UK BM8:Germany B1MR34:Brazil BMRN:Austria

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

https://www.biomarin.com

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Biomarin Pharmaceutical Headlines

No Headlines